Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company whose news flow centers on the development of TERN-701, a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor for chronic myeloid leukemia (CML). Company updates describe TERN-701 as the lead program in a focused oncology pipeline, with detailed disclosures on clinical data, regulatory interactions and trial design.
News about Terns frequently highlights results from the CARDINAL trial (NCT06163430), a global multicenter Phase 1/2 study of TERN-701 in previously treated chronic phase CML. Press releases and related SEC filings summarize major molecular response (MMR) and deep molecular response (DMR) rates, safety and tolerability findings, and outcomes in heavily pretreated or difficult-to-treat patient subgroups, including those with prior exposure to other tyrosine kinase inhibitors.
Investors following TERN can also find announcements about regulatory milestones, such as U.S. FDA Fast Track designation for TERN-701 in CML, and information on anticipated clinical priorities and program milestones. Terns’ news includes details on scientific presentations at major conferences like the American Society of Hematology (ASH) Annual Meeting and other healthcare conferences where updated CARDINAL data and development plans are discussed.
In addition, Terns issues news on capital markets activity, including underwritten public offerings of common stock intended to support research, clinical trials, development and manufacturing of key product candidates. Corporate updates may also cover decisions regarding legacy metabolic programs, such as TERN-501, TERN-801 and TERN-601, and the company’s strategy to seek partners for these assets. This news page aggregates such disclosures, offering a centralized view of Terns Pharmaceuticals’ clinical progress, financial developments and strategic focus in oncology.
Terns Pharmaceuticals reported Q1 2021 financial results and corporate updates, highlighting advancements in their NASH clinical programs. With top-line data for the Phase 2a LIFT study of TERN-101 expected in June 2021, the company emphasizes the focus on safety and multiple non-invasive endpoints. The oversubscribed IPO raised $147 million, enhancing their financial position. R&D expenses rose to $8.7 million, while the net loss increased to $13.3 million from $9.2 million a year earlier. Cash reserves of $195.6 million are projected to support operations through 2024.
On April 7, 2021, Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced its participation in the 19th Annual Virtual Needham Healthcare Conference. The presentation is set for April 14 at 11:40 a.m. ET. Interested parties can access a live audio webcast through the conference and Terns’ website, with a replay available for 30 days post-event. Terns focuses on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, utilizing clinically validated mechanisms to benefit patients.
Terns Pharmaceuticals reported a strong financial position with $75 million in cash as of Q4 2020, following an upsized IPO that raised approximately $147 million in February 2021. The company is advancing its pipeline for treating non-alcoholic steatohepatitis (NASH) with three clinical-stage candidates: TERN-101 (Phase 2a), TERN-201 (Phase 1), and TERN-501 (Phase 1). Key milestones include expected data readouts in mid-2021. The company reduced total net loss to $40.6 million from $68.8 million in 2019, indicating improved cost management.
Terns Pharmaceuticals has initiated dosing in a Phase 1 clinical trial for TERN-501, a selective thyroid hormone receptor beta (THR-β) agonist targeting non-alcoholic steatohepatitis (NASH). Designed for high metabolic stability and enhanced liver distribution, TERN-501 aims to demonstrate improved safety and efficacy compared to other THR-β agonists. The trial, involving approximately 90 participants, will assess safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers, with initial top-line data expected in the second half of 2021.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) will present data on its NASH clinical programs at the NASH-TAG Conference 2021 from March 11-13. The company will give an oral presentation on targeting vascular adhesion protein-1 (VAP-1) inhibition for NASH treatment and showcase its FXR agonist, TERN-101. The oral presentation is scheduled for March 13 at 6:45 PM MST. Terns aims to initiate a Phase 1b trial for TERN-201 in patients in H1 2021 and expects Phase 2a data for TERN-101 by Q3 2021. Both therapies target chronic liver diseases, aiming for significant clinical benefits.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, announced its participation in the Cowen 41st Annual Health Care Conference. Management will present on March 4 at 9:50 a.m. ET, with a live audio webcast available on their website. Additionally, Terns will join a NASH panel discussion on March 2 from 12:50-1:50 p.m. ET. The company focuses on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) has successfully closed its initial public offering of 7,500,000 shares at $17.00 each. Additionally, underwriters exercised their option to purchase 1,125,000 shares, leading to projected gross proceeds of approximately $146.6 million. This funding aims to support the development of Terns' pipeline targeting non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The offering was facilitated by J.P. Morgan, Goldman Sachs & Co. LLC, and Cowen. The shares were registered with the SEC, and the entire offering is expected to close by February 12, 2021.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the pricing of its upsized initial public offering of 7,500,000 shares at $17.00 each, totaling gross proceeds of $127.5 million. The offering, which includes a 30-day option for underwriters to purchase an additional 1,125,000 shares, is set to close on February 9, 2021. Terns’ common stock will trade on the Nasdaq under the symbol 'TERN' starting February 5, 2021. Major underwriters include J.P. Morgan, Goldman Sachs, and Cowen.